Tipelukast

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameTipelukast
Drug Alias Nametipelukast泰鲁司特tipelukastumMN-001KCA-757
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThromboxane A2 receptor antagonistsPhospholipase C inhibitorsCysteinyl leukotriene receptor 1 antagonists +[6] 
TargetsCysteinyl leukotriene receptor 1Thromboxane A2 receptorPhosphodiesterase 3 +[6] 
Therapy Area/IndicationsHypertriglyceridemiaHypercholesterolemiaDiabetes Mellitus, Type 2 +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesKyorin Holdings Inc
China Registration ClassN/A

Develop Information

Active CompaniesMedicinova Inc
Inactive CompaniesN/A
Active IndicationsHypertriglyceridemiaDiabetes Mellitus, Type 2Idiopathic Pulmonary Fibrosis +[4] 
Inactive IndicationsHypercholesterolemiaCystitis, Interstitial

Other Information

ATC CodeN/A
Related LinksKEGG